Hancock Jaffe Laboratories Holdings Inc. Warrant (NVNBW)

Overview

enVVeno Medical Corporation is a clinical-stage medical device company dedicated to advancing the treatment of venous diseases through innovative bioprosthetic tissue-based solutions. Initially known as Hancock Jaffe Laboratories, Inc., the company underwent a name change to enVVeno Medical Corporation in October 2021, marking a new chapter in its mission to improve the standard of care for patients suffering from venous conditions. Founded in 1999 and headquartered in Irvine, California, enVVeno Medical Corporation leverages its expertise in medical device development to address the unmet needs of patients with Chronic Venous Insufficiency (CVI) and other venous disorders.

Products and Services

• VenoValve

A surgical implant designed for the treatment of Chronic Venous Insufficiency (CVI), the VenoValve represents enVVeno Medical Corporation's flagship product. Aimed at patients suffering from this debilitating condition, the VenoValve is surgically placed in the femoral vein. It functions as a one-way valve, restoring proper blood flow in the leg by preventing the backward flow of blood. This innovative approach offers hope for improving the quality of life for those affected by CVI, showcasing enVVeno Medical Corporation's commitment to addressing complex venous diseases with advanced medical technologies.

• enVVe

enVVe serves as a non-surgical, transcatheter-based venous valve replacement solution, signifying another key component of enVVeno Medical Corporation's product line aimed at treating CVI. This revolutionary product offers a less invasive alternative to traditional surgery, designed to replicate the function of healthy venous valves. By facilitating the restoration of normal blood flow through minimally invasive means, enVVe exemplifies the company's innovation in providing effective treatment options for patients seeking relief from the symptoms of Chronic Venous Insufficiency.